Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Acid-reducing Agents on Sotorasib PK
NCT05599828Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at Day 11, Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration at Day 11 and 1 more. Started Jul 2020; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05599828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599828.